The S. crispus subfraction F3 exerts its anti-cancer effects in breast cancer cells by modulating the glycolytic and migratory activities via the inhibition of GLUT1 localization to the cell membrane and the inhibition of the AKT/mTOR/HIF1α pathway that potentially inhibits the expression of glycolytic-related molecules. The gene discussed is SLC2A1; the disease is cancer.